Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
F&G: 54
5.941,47 S&P · 21,00 Vola-Index · 104.799,81 BTC · 1,14773 EURUSD
System-State: Number of processed items 48.125 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US92539P1012
State: 19.06.2025 | 12PM
Do you already know our new terminal view? Click here.
FIGI: BBG00P33TCZ8
VERV

Verve Therapeutics, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Verve Therapeutics, Inc.
ISIN
US92539P1012
TICKER
VERV
MIC
XNAS
REUTERS
VERV.OQ
BLOOMBERG
VERV US
Thu, 19.06.2025       Verve Therapeutics

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus ...
Tue, 17.06.2025       Verve Therapeutics

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling ...
Tue, 17.06.2025       Verve Therapeutics

The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. I...
Silent Ad
Sat, 26.10.2024       Verve Therapeutics

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. So what: If you p...
Wed, 11.09.2024       Verve Therapeutics

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular di...
Mon, 09.09.2024       Verve Therapeutics

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defenda...
Tue, 03.09.2024       Verve Therapeutics

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular di...
Sun, 01.09.2024       Verve Therapeutics

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defenda...
Thu, 29.08.2024       Verve Therapeutics

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. ...
Wed, 28.08.2024       Verve Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) and reminds investors of the October 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Silent Ad
Tue, 27.08.2024       Verve Therapeutics

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Verve Therapeutics investors under the fe...

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S